Product

IASOdopa

iasodopa header

Marketing Authorizations

Country
Product Name
MA number
Date of registration
PDF
France
IASOdopa
34009 578 256 2 1 (15mL)/ 34009 566 897 8 1 (25mL)
16.11.2006
Austria
IASOdopa
4-00032
29.11.2007
No data was found
No data was found
No data was found
No data was found
No data was found
No data was found
No data was found
No data was found
Germany
IASOdopa
69747.00.00
31.08.2007
No data was found
No data was found
Italy
Fluorodopa IASON
038449031(20mL)/ 038449043 (11mL)
12.09.2013
No data was found
No data was found
No data was found
No data was found
No data was found
No data was found
No data was found

6-fluoro-(¹⁸F)-L-dopa is indicated for use with positron emission tomography (PET) in adults and paediatric population.

Neurology

PET with 6-fluoro-(18F)-L-dopa is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum. It can be used for diagnosis of Parkinson’s disease and differentiation between essential tremor and parkinsonian syndromes.

Oncology

Among medical imaging modalities, PET with 6-fluoro-(18F)-L-dopa provides a functional approach of pathologies, organs or tissues where enhanced intracellular transport and decarboxylation of the amino acid dihydroxyphenylalanine is the diagnostic target. The following indications have been particularly documented:

Diagnosis

  • Diagnosis and localisation of focal hyperplasia of beta islet cells in the case of hyperinsulinism in infants and children
  • Diagnosis and localisation of paragangliomas in patients with a gene mutation of the succinate dehydrogenase D variant
  • Localisation of pheochromocytoma

Staging

  • Phaeochromocytoma and paraganglioma
  • Well differentiated neuroendocrine tumours of midgut.

Detection in case of reasonable suspicion of recurrences or residual disease

  • Primary brain tumours of all grades of differentiation.
  • Phaeochromocytoma and paraganglioma
  • Medullary thyroid cancer with elevated serum levels of calcitonin
  • Well differentiated neuroendocrine tumours of midgut
  • Other endocrine digestive tumours when somatostatin receptor scintigraphy is negativeThis medicinal product is for diagnostic use only. 

Therapeutic indications. This medicinal product is for diagnostic use only.

Do you want to know more about our products?

For inquiries please contact us, we will be happy to assist you!

Find out more about Curium’s global footprint

Scroll to Top
Iason Logo Alt
curium logo

Welcome to our new website

You've been redirected from iason.eu to our new domain curium-austria.com

Curium acquired IASON in June of 2021, further expanding its footprint in Europe for its broad portfolio of life saving diagnostic solutions. Learn more on Curium’s website